Related Experiment Video
Updated: Aug 25, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Case report: Alpelisib-induced Stevens-Johnson syndrome
Christine Jane Kurian1, Akshay Desai2, William Rafferty3
1Department of Hematology and Medical Oncology, MD Anderson Cancer Center at Cooper University Healthcare, Camden, NJ, United States.
This report details the first case of Stevens-Johnson Syndrome (SJS) in a patient treated with alpelisib for advanced breast cancer. Early drug cessation and steroid treatment led to symptom improvement, highlighting the need for vigilant monitoring.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Alpelisib is approved for PIK3CA-mutated advanced breast cancer.
- Known side effects include alopecia and rash.
- No prior cases of Stevens-Johnson Syndrome (SJS) linked to alpelisib existed.
More Related Videos
Related Concept Videos
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

